First Opinion By Peter Kolchinsky and Jessica Sagers We need a Public Domain Day to highlight when drugs go off patent
Pharmalot By Ed Silverman AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument
Pharmalot By Ed Silverman Supreme Court to decide a patent case with big implications for small drug makers
First Opinion By Othman Laraki Proposed patent legislation would block research, stifle innovation, and harm patients
Pharmalot By Ed Silverman FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed
Pharmalot By Ed Silverman Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug
Pharmalot By Ed Silverman Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?
Pharmalot By Ed Silverman Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers
Pharmalot By Ed Silverman Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament
Pharmalot By Ed Silverman Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying
Pharma By Ed Silverman and Matthew Herper Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation
Pharmalot By Ed Silverman Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again
Pharmalot By Ed Silverman Trump administration report would preclude reclaiming patents as a way to lower drug prices
Pharmalot By Ed Silverman Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices
Pharmalot By Ed Silverman Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert
Pharmalot By Ed Silverman Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal
Pharmalot By Ed Silverman Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment
Pharmalot By Ed Silverman U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise
Pharmalot By Ed Silverman Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds
Pharmalot By Ed Silverman Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug
Pharmalot By Ed Silverman With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold
Pharmalot By Ed Silverman Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?
Pharmalot By Ed Silverman NIH is urged to probe Aegerion patents for failing to disclose federal funding
Pharmalot By Ed Silverman Tens of millions of people continue to lack access to hepatitis C medicines
Pharmalot By Ed Silverman HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding
Pharmalot By Ed Silverman Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries
Pharmalot By Ed Silverman Pharmalittle: Will Jeff Sessions really go after opioid makers? Mylan pursues a biosimilar Botox